Drug Trial Radar · NCT00255450
A Crossover Safety Study of Ferumoxytol Versus Placebo
Last checked: Nov 20, 2026Latest source record: Nov 11, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
750
Actual
Start
Jan 2005
Primary completion
Not stated
Study completion Aug 2006
Sponsor
- Lead sponsor
- AMAG Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This crossover safety study will evaluate the safety of a single dose of ferumoxytol compared to placebo in patients with chronic kidney disease.
Conditions
- Anemia
Interventions
ferumoxytol or placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety evaluated by physical examinations, vital signs, laboratory tests and patient monitoring and evaluation.
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Mountain View, California
Site not named
New Haven, Connecticut
Site not named
Washington D.C., District of Columbia
Site not named
Ocala, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Newnan, Georgia
Site not named
Peoria, Illinois
Site not named
Shreveport, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
St Louis, Missouri
Site not named
Broken Bow, Nebraska
Site not named
Lebanon, New Hampshire
Site not named
Flushing, New York
Site not named
New York, New York
Site not named
New York, New York
Site not named
Orchard Park, New York
Site not named
Raleigh, North Carolina
Site not named
Columbus, Ohio
Site not named
Portland, Oregon
Site not named
Erie, Pennsylvania
Site not named
Lancaster, Pennsylvania
Site not named
Greenville, South Carolina
Site not named
Sumter, South Carolina
Site not named
Chattanooga, Tennessee
Site not named
Knoxville, Tennessee
Site not named
Austin, Texas
Site not named
Houston, Texas
Site not named
San Antonio, Texas
Site not named
Alexandria, Virginia
Site not named
Charlottesville, Virginia
Site not named
Chesapeake, Virginia
Site not named
Norfolk, Virginia
Site not named
Bluefield, West Virginia
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.